(R) Cantargia advance antibody CAN04 development after positive pre-IND meeting
(WorldNews Sweden)

Cantargia AB announced today that the pre-IND meeting regarding the clinical development of antibody CAN04 was held with the US FDA. The purpose of the meeting was to discuss the available information on CAN04, including data from the first-in-human phase I trial, and a proposed new phase I clinical trial with CAN04 in combination with an immune checkpoint inhibitor under a US IND. As a result of the meeting, Cantargia is advancing the development of CAN04 and will apply for a US IND around New Year`s. Cantargia develops antibody-based pharmaceuticals targeting the interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high...